medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2010, Number 4

<< Back Next >>

Rev Esp Med Quir 2010; 15 (4)

Microalbuminuria, a sub valuated diagnosis resource in the timely detection of chronic renal failure

Méndez DA, Rivera RG

Language: Spanish
References: 34
Page: 237-241
PDF size: 67.44 Kb.


ABSTRACT

Chronic the renal disease (ERC) is a problem of public health at world-wide level, the lack of human, financial resources and of infrastructure they indicate it like a catastrophic disease. On the other hand, the incidence is increased day with day and the strategies of prevention of the renal damage are inefficient reason why it is imperative to identify renal damage of an opportune way. The determination of microalbuminuria with reactive strip in risk populations is an effective tool in the detection of the renal damage, of compared costs of investment with the generated ones by the substitute therapies of dialysis and simple to make. It is necessary that the systems of health in Mexico implement programs of opportune detection and integral attention for this disease, in where the initial identification of the renal damage allows to offer specific the dietetic and pharmacologic treatment, the opportune reference to the specialist, the delay of the progression of the ERC and diminution of the number of incom e to dialysis.


REFERENCES

  1. Treviño BA. Insuficiencia renal crónica: enfermedad emergente, catastrófica y, por ello, prioritaria. Cirugía y Cirujanos 2004;72(1):3-4.

  2. Méndez DA. Epidemiología de la insuficiencia renal crónica en México. Diálisis y Trasplante 2010;31(1):7-11.

  3. Brakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? Journal Clinical Hypertension 2001;3(2):99-102.

  4. Amato D, Álvarez AC, Castañeda LR, Rodríguez E, et al. Prevalence of chronic kidney disease in an urban Mexican population. Kidney International 2002;68(Suppl 97):S11-S17.

  5. Méndez DA. Prevención del daño renal. Manejo de la enfermedad renal crónica en el primer nivel de atención médica. Atem Fam 2010;17(3):74-78.

  6. Alcazar AR, Orte ML, Otero GA. Enfermedad renal crónica avanzada. Nefrología 2008;(Supl 3):3-6.

  7. Aguilar CA, Velázquez MO, Gómez FJ, González A, et al. For the ENSA 2000 Group. Characteristics of patients with type 2. Diabetes in México. Diabetes Care 2003;26(7):2021-2026.

  8. Robles NR, Fernández CE, Sánchez CE, Cuberto JJ. Incidencia creciente de nefropatía diabética en la provincia de Badajoz durante el periodo 1991-2006. Nefrología 2009;29(3):244-248.

  9. Evaluación de los riesgos considerados en el Programa de Administración de Riesgos. Dirección de Finanzas. Coordinación de Administración de Riesgos Institucionales. Instituto Mexicano del Seguro Social 2007;p:39-44.

  10. Tuttle KR. Renal manifestations of the metabolic syndrome. Nephrol Dial Transplant 2005;20:861-864.

  11. García de Vinuesa S. Factores de progresión de la enfermedad renal crónica. Prevención secundaria. Nefrología 2008;(Supl 3):17-21.

  12. Rossi CE, Nicolucci A, Pellegrini F, Comaschi A, et al. Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of renal and cardiovascular risk in Diabetes) Study. Nephrol Dial Transplant 2008;23:1278-1284.

  13. Baekken M, Os I, Sandvik L, Oektedalen O. Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population. Nephrol Dial Transplant 2008;23:3130-3137.

  14. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007;2:581-590.

  15. Shin-ichi A, Masakazu H, Daisuke K, Hideki H, et al. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 2007;56:1727-1730.

  16. Ibsen H, Olsen MH, Wachtell K, Lindholm LH, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005;45:198-202.

  17. Festa A, D’Agostino R, Howard G, Mykkänen L, et al. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study. Kidney International 2000;58:1703-1710.

  18. Lindholm L, Ibsen H, Dahlof B, Devereux RB y col. Riesgo de diabetes de nueva aparición en el estudio de intervención con losartán para la reducción de parámetros clínicos finales en hipertensión (LIFE). Journal Hypertension 2002;20:1879-1886.

  19. Fernández FI, Páez JM, Hermosín BT, Vazquez GP, et al. Rapid screening test evaluation for microalbuminuria in diabetes mellitus. Acta Diabetes 1998;35:199-202.

  20. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, et al. Renoprotecting effect of the angiotensin-receptor antagonist irbesartan impacting with nephropathy due type 2 diabetes (Study IRMA). N Engl J Med 2001;345:851-860.

  21. Bilious R, Chaturvedi N, Sjølie AK, Fuller J, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes. Three randomized trials. Ann Intern Med 2009;151:11-20.

  22. Johannes FE, Mann RE, Schmieder LD, Matthew J, et al. For the TRANSCEND Study. Effect of telmisartán on renal outcomes. A randomized trial. Ann Intern Med 2009;151:1-10.

  23. Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C. On behalf of the VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008;23(10):3174-3183.

  24. Weber MA, White WB, Sica D, Bakris GL, et al. Antihypertensive efficacy of the novel angiotensin receptor blocker azilsartan medoxomil in combination with amlodipine. J Hypert 2010;28:279-280.

  25. Kunz R, Friedrich C, Wolbers M, Johannes FE. Metaanalysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Int Med 2008;148(1):38-40.

  26. Atsushi H, Keizo Y, Toru M, Kunihiko H, et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (Impact of OLmesartan on progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound) trial. J Am Coll Cardiol 2010;55:976-982.

  27. Sreebhushan R, Rammohan P. Endothelial dysfunctions in patients with essential hypertension: effect of olmesartan vs telmisartan a randomized, comparative, open label parallel group study. Nephrol Dial Trasplant Plus 2009;2(Suppl 2):514-521.

  28. Punzi H, Neutel JM, Kereiakes DJ, Shojaee A, et al. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZor Trial Evaluating blood pressure reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis 2010;4(4):209-221.

  29. Burnett JC. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999;17(Suppl 1):S37-43.

  30. Diagnóstico y tratamiento de la diabetes mellitus tipo 2. Guía de Práctica Clínica, IMSS. Coordinación de Unidades Médicas de Alta Especialidad. División de Excelencia Clínica, 2009.

  31. Taal MW, Nenov VD, Wong W, Satyal SR, et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 2001;12(10):2051-2059.

  32. Parving HH, Persson F, Lewis JB, Lewis E, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446.

  33. Coresh J, Astor B, Greene T, Eknoyan G y col. Prevalencia de la enfermedad renal crónica y disminución de la función renal en la población adulta de Estados Unidos de América: Tercer encuesta nacional de salud y nutrición. Am J Kidn Dis 2003;41(1):1-12.

  34. Simerjot JK, Silverstein KD, Barrett CE. A prospective study of albuminuria and cognitive function in older adults. The Rancho Bernardo Study. Am J Epidemiol 2010;171:277-286.




2020     |     www.medigraphic.com